A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).
about
Memantine for dementiaVascular dementiaN-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's diseasePost-stroke cognitive impairment: epidemiology, mechanisms and managementMemantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis.The effects of memantine on prepulse inhibition.Binswanger's disease: toward a diagnosis agreement and therapeutic approachIschemic brain injury in cerebral amyloid angiopathyDementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.Effect of acupuncture treatment on vascular cognitive impairment without dementia: study protocol for a randomized controlled trial.Screening for cognitive decline following single known stroke using the Mini-Mental State Examination.Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia.Vascular cognitive impairment: disease mechanisms and therapeutic implications.Evaluation and management of the elderly patient presenting with cognitive complaints.Evaluation of memantine for the treatment of Alzheimer's disease.Memantine: an antiglutamatergic option for dementia.Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias.Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.NMDA receptors in clinical neurology: excitatory times ahead.Memantine in the treatment of mild-to-moderate Alzheimer's disease.Target symptoms and outcome measures: cognition.Therapeutic issues in vascular dementia: studies, designs and approaches.Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation.Vascular dementia: pharmacological treatment approaches and perspectivesVascular dementia: prevention and treatment.Alzheimer's and non-alzheimer's dementia: a critical review of pharmacological and nonpharmacological strategies.Memantine: efficacy and safety in mild-to-severe Alzheimer's disease.Inflammation and aging: can endocannabinoids help?Neuroprotection in glaucoma: drug-based approaches.Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review.Current concepts in vascular cognitive impairment and pharmacotherapeutic implications.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias.Memantine in dementia: a review of the current evidence.Drug therapy of post-stroke aphasia: a review of current evidence.Future directions in treatment of brain metastases.Treatment of brain metastases in lung cancer: strategies to avoid/reduce late complications of whole brain radiation therapy.Understanding and preventing the development of post-stroke dementia.
P2860
Q22252980-1CD0BAAF-38E4-4ECA-8000-0307365FFC6AQ24629003-213928A7-4B6D-4BF3-9380-AC0E6490C0DDQ26825619-6303D023-09A2-4111-9F6F-92703EDA39CBQ26865422-681AAC33-4710-4500-8BAC-888076752B7BQ30366961-C32FFD15-F031-45C8-8EBF-1750491C10D9Q30485038-BDE33078-09D0-4014-A6E9-76A26486EBF3Q30848732-34361625-F0EE-43A6-A00F-3AEE2CBE7646Q30945201-1C79CF5B-A069-4298-807D-06AE4E4E390DQ33160127-3A84CB83-D4A9-4C91-AE6E-1A255C9D1B3BQ33165693-32A2F20C-E353-4B12-A156-CFB03DCD45F7Q33967781-CF17D850-0F20-47F7-8363-5AE9A1A3A925Q34565375-C5680EFC-5ED2-4F2C-B769-AD2534280BF0Q34956402-5DA8862A-A279-45EB-AFC1-6F8480FD56C3Q35117821-334F3F9C-E7EE-4781-A79E-B0420D83865DQ35197111-EDEECA0A-1DEF-4FB2-9A2B-C6080A670067Q35447239-769184C6-1147-4B07-890D-8FBDC4FFEFE1Q35594009-9E07D1B8-F6E2-4363-A6B9-0C2BAEEAEFB4Q35683081-5D4C10EF-E171-44B7-ADCF-49B6A4018521Q36103890-EA88B7D1-D056-4AA8-9E31-F4CB1CC3653FQ36632771-50AC34E9-CE07-4DDB-B8BA-D66E7963859EQ36660216-03DBACF1-D08B-48EC-86F4-5F993089CB45Q36719691-3767A06E-3A9A-4E3E-AD67-11C84ADF8067Q36806620-2E607581-C92E-41F2-9416-1DF4B4E005BBQ36808830-9F6588BE-FD01-4A19-8CA2-BB7F879DBA30Q36848206-E7237545-90D4-4761-80A0-EF283171EAD9Q37017429-613C8F29-8DBC-47BF-9F6C-637E0016A9E7Q37018866-757745B1-3BD0-4FC4-B87C-F8B38F98FDD6Q37106942-F7EAE2AE-B7C1-4424-9E68-FCA7454A94B0Q37125743-CE0C44A7-5683-433E-8376-ACC647D822D9Q37133525-2288374C-8C95-4879-83B5-72600742AD33Q37180770-A7F28B04-D4C9-457A-8ADF-296E21CFDBCBQ37187732-CDB82116-B97F-447B-9AB5-5F7DCA394CB6Q37396299-F33449A2-7973-4673-9A66-5DAC0ABDFF28Q37543915-732C646A-A2C0-465F-8ADA-06BE0FEA4B74Q37834619-C3E9CBAE-3749-4F26-BC34-2B96A509B57FQ37850821-EE33B6ED-FB1D-4434-BAB2-B2749CDB8A8FQ37918433-9D0F59D0-D238-495D-8E82-EF538E16CCBCQ38110294-6D5C21CA-52FC-4C5A-B51E-3EFC975D083AQ38139324-B2460BC7-A9B7-4215-A1FE-C876BF1C36AFQ38238144-3F6FA996-5C90-419C-B1ED-2D44209CF24D
P2860
A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
A double-blind, placebo-contro ...... te vascular dementia (MMM500).
@en
A double-blind, placebo-contro ...... te vascular dementia (MMM500).
@nl
type
label
A double-blind, placebo-contro ...... te vascular dementia (MMM500).
@en
A double-blind, placebo-contro ...... te vascular dementia (MMM500).
@nl
prefLabel
A double-blind, placebo-contro ...... te vascular dementia (MMM500).
@en
A double-blind, placebo-contro ...... te vascular dementia (MMM500).
@nl
P2093
P1476
A double-blind, placebo-contro ...... te vascular dementia (MMM500).
@en
P2093
A Stöffler
H J Möbius
MMM 500 group
P304
P356
10.1097/00004850-200211000-00005
P577
2002-11-01T00:00:00Z